Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

eMI Aesthetics vs GoodRx

eMI Aesthetics
Graded #104

Higher grade

vs+0.7000000000000028
GoodRx
Graded #116

Lower grade

The verdict

eMI Aesthetics takes it — 70.3/100 to 69.6/100, but only just.

eMI Aesthetics grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMI Aesthetics is a US direct-to-consumer telehealth brand offering doctor-guided GLP-1 weight loss programs to eligible patients in all 50 states. GoodRx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +7
73
80
Dose & formulationeMI Aesthetics +14
84
70
Clinical oversighteMI Aesthetics +1
70
69
Labs & monitoringEven
51
51
FulfillmentGoodRx +4
77
81
Contract termsEven
55
55
eMI Aesthetics · left barGoodRx · right bar

The numbers

MetriceMI AestheticsGoodRx
WeighScore70.3/10069.6/100
GradeCC
Scorecard rank#104#116
Semaglutide$179/mo (all doses, compounded)Not disclosed
TirzepatideNot disclosed$299/mo (brand Zepbound)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualYesInjection only
eMI Aesthetics

Graded #104 · C

Strengths

  • Available to eligible patients in all 50 states
  • Offers both semaglutide and tirzepatide, plus an oral semaglutide option
  • Intake and provider visits run through OpenLoop Health, an established telehealth network

Where it loses points

  • Full per-drug pricing is not shown before intake; only an 'as low as 179/month' starting rate is published
  • No fill pharmacy or named medical director is publicly listed
  • Support appears limited to email, with no phone number or hours published
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard